Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.


Creative Commons License

Ongoren S. , Eskazan A. , Suzan V. , Savci S., Erdogan O., Berk S., ...Daha Fazla

Hematology (Amsterdam, Netherlands), cilt.23, sa.4, ss.212-220, 2018 (SCI Expanded İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 23 Konu: 4
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1080/10245332.2017.1385193
  • Dergi Adı: Hematology (Amsterdam, Netherlands)
  • Sayfa Sayıları: ss.212-220

Özet

Objectives: Newer tyrosine kinase inhibitors (TKIs) (bosutinib, ponatinib) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be utilized as a salvage therapy in patients with chronic myeloid leukemia (CML) who failed two lines (imatinib -> nilotinib or imatinib -> dasatinib) of TKI therapy. However, these TKIs are not available in many countries and not all patients can undergo allo-HSCT.